An intriguing approach to achieving an optimal “hot” tumor condition could involve combinatorial therapies, such as a combination of ImmTACs with immune checkpoint inhibitors (ICI), targeted therapies, or novel approaches like STING agonists. The gene discussed is STING1; the disease is neoplasm.